Responsiveness to cetuximab without mutations in EGFR.

摘要: To the Editor: A large amount of information suggests that mutations in kinase domain epidermal growth factor receptor (EGFR) are critical for efficacy EGFR inhibitors.1–3 However, effect on response to cetuximab has not been directly investigated. Barber et al.4 reported absence colorectal cancers and speculated were required cetuximab, since it was an efficacious agent against this type tumor.5 We sequenced (exons 18, 19, 21) tumor samples from 38 . . .